Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 5,259 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Autoimmune Disease Clear all
Completed Phase 2 Interventional

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

NCT00071838
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

NCT03933943
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
LY3361237, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Anniston, Alabama • Clearwater, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 21, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional

Diabetes Multimorbidity Typology, Trajectory, and Feasibility of an Audio Diary Mobile Application to Support Self-management

NCT07474376
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Fabla Mobile App
Other
Lead sponsor
Emory University
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis

NCT00103974
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BHT-3009-01
Biological
Lead sponsor
Bayhill Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Phoenix, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2008 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

Interferon-Alpha for Diabetes Mellitus Type 1

NCT00024518
View directory record Official record
Conditions
Insulin-Dependent Diabetes Mellitus
Interventions
30,000 units hrINF-alpha, 5,000 hrINF-alpha, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
5
States / cities
Bethesda, Maryland • Saint Paul, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Telemedicine for Adolescents With Insulin-dependent Diabetes

NCT02155855
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Telemedicine, Control
Other
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 21, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional

EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))

NCT06631638
View directory record Official record
Conditions
Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congential Hip Dysplasia, Avascular Necrosis of the Femoral Head, Certain Cases of Ankylosis
Interventions
EMPHASYS Cup with VHN
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Gainesville, Florida • Gastonia, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 2:09 PM EDT
Withdrawn Not applicable Interventional

Tissue Sodium in Autoimmune Disease

NCT02525835
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Low Dietary Sodium, High Dietary Sodium
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

NCT01356940
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dalfampridine ER, placebo
Drug
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Web-based Support to Manage Arthritis Pain

NCT01463189
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Interventions
painACTION: Arthritis
Behavioral
Lead sponsor
Inflexxion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 21, 2026, 2:09 PM EDT
Active, not recruiting No phase listed Observational

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

NCT07757568
View directory record Official record
Conditions
Multiple Sclerosis (MS) Relapsing Remitting
Interventions
Vumerity, Tecfidera
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 2:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients

NCT00094068
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 2:09 PM EDT
Completed No phase listed Observational

Antiphospholipid Syndrome Collaborative Registry (APSCORE)

NCT00076713
View directory record Official record
Conditions
Antiphospholipid Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
7
States / cities
Atlanta, Georgia • Baltimore, Maryland • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 21, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

NCT07599982
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Interventions
MODI Algorithm
Device
Lead sponsor
DreaMed Diabetes
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 2:09 PM EDT
Not listed Not applicable Interventional

Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)

NCT06515782
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

NCT01563185
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
800 mg ibuprofen/26.6 mg famotidine
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
New Orleans, Louisiana • Boston, Massachusetts • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044408
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
13
States / cities
Long Beach, California • Norwalk, Connecticut • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 21, 2026, 2:09 PM EDT
Terminated Not applicable Interventional Results available

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

NCT00564018
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin detemir, Glargine, NPH
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Not applicable Interventional

Assistive Device Training in Multiple Sclerosis

NCT02408718
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Assistive Device Training
Behavioral
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

NCT00665626
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib disodium (R935788), Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Aventura, California • Palm Desert, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

NCT02762123
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986142 200mg, BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin), BMS-986142 350mg
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

NCT02460978
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo for dapagliflozin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
47
States / cities
Concord, California • Fresno, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

NCT03110315
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue, Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 2:09 PM EDT
Not listed Not applicable Interventional

A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections

NCT01045954
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Lispro Insulin and glargine insulin
Drug
Lead sponsor
Diabetes Care Center
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Salinas, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 21, 2026, 2:09 PM EDT